The following information was provided by the licensee via phone and email:
A routine yttrium-90 (Y-90) microsphere radioembolization treatment performed in the hospital on July 29, 2026. The radiopharmaceutical used in this treatment, Y-90 microspheres, are manufactured under the brand name Therasphere, which is produced by Boston Scientific (Marlboro, MA, USA). In this procedure, a catheter is guided through the patient's vasculature until it reaches the blood vessels feeding a tumor in the liver. From this position, the radiopharmaceutical is administered to the tumor by injection through the catheter. During the procedure, the radiopharmaceutical was administered by an authorized user (AU) on July 29, 2026. The treatment was delivered as planned, with 13.5 mCi administered to a hepatocellular carcinoma tumor in the left lobe of a patient's liver. Post-treatment Bremsstrahlung imaging was performed to verify localization of the radiopharmaceutical. Later, an AU interpreted the post-treatment imaging and identified distribution of the radiopharmaceutical to the stomach and spleen. Dose projections are forthcoming due to the complexity of the procedure. The licensee is working through the investigation of the incident and will follow the NRC guidelines for communicating with the patient and submitting a written report.
A Medical Event may indicate potential problems in a medical facility's use of radioactive materials. It does not necessarily result in harm to the patient.